Morphic Therapeutic, Inc. is a biopharmaceutical company applying its proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
The stock is +20% as I’m typing.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”